[AG120-C-002]-lay summary in cCS subgroup-2025.03.21.en

Home » A Phase 1, Multicenter, Open-Label, Dose-Escalation and Expansion, Safety, Pharmacokinetic, Pharmacodynamic, and Clinical Activity Study of Orally Administered AG-120 in Subjects with Advanced Solid Tumors, Including Glioma, with an IDH1 Mutation » [AG120-C-002]-lay summary in cCS subgroup-2025.03.21.en

© 2025 LES LABORATOIRES SERVIER, an incorporated company of Servier.
All Rights Reserved. Servier does not sell its products over the Internet.

Accessibility